As an update to my previous comments, I had a very good telephone conversation today with the Chief Technology Officer of IMBIO. He was very knowledgeable, informative and generous with his time. It is now clear to me, based on the information he provided, that the CANARY technology, whose status I’ve been trying to clarify, is still under review by the FDA and is probably still a few years from being commercially available.
This really has addressed my concern. I had wanted to understand whether the CANARY technology was available, or was soon to be made available. As with any cancer patient, if it had been available and had already proved to be very prospective in enhancing the accuracy of long nodule diagnosis, I would have wanted to avail myself of it. But, as this is not yet the case, I believe I can feel assured that I’m not missing out on a medical opportunity. And while this technology is not available at this time, hopefully it will come to fruition in the not-too-distant future and will be of great value to those who can benefit from it.
I believe in “paying it forward”, Colleen. Therefore, first I will keep you apprised of any significant developments that I become aware of. Second, if you believe that I can be of some assistance, as a non-expert, in providing a measure of guidance to others based on my own investigations (again, achieved with your considerable help), I would be very pleased to do so. In this regard, although my question regarding CANARY’s availability has now been answered, I will nevertheless continue my research into the overall topic of lung nodule diagnosis and prognosis.